ASXL1 and CD4+/CD56+ hematodermic neoplasm: The mutations affected genes that are recurrently altered in clonal haematopoiesis, myeloid leukaemia and BPDCN, including TET2 (11 out of 16 patients, 69%), ASXL1 (9 out of 16 patients, 56%) and RNA splicing factors (9 out of 16 patients, 56%)1–3,12,17,18.